Hagens Berman said investors who bought shares between Nov. 25, 2025 and May 4, 2026 may seek lead-plaintiff status by Aug. 17, 2026 after the company cut guidance and slashed its dividend.
Embecta Corp. is facing a securities class action tied to allegations that it misled investors about the strength of its pen needle business before a sharp deterioration in quarterly results and full-year expectations. Hagens Berman said the proposed case covers investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026, with an Aug. 17, 2026 lead plaintiff deadline. The claims center on repeated statements during the class period that Embecta’s insulin pen business was stable and durable, messaging that underpinned its February 5, 2026 guidance reaffirming 2026 adjusted EPS of $2.80 to $3.00 and its stated plan to maintain the dividend. The complaint alleges those assurances were misleading because the company knew, or recklessly disregarded, weakness in the pen needle market that was likely to disrupt annual guidance and second-quarter results. The dispute intensified after Embecta reported Q2 2026 adjusted EPS of $0.27 on May 5, 2026, down about 61% sequentially and year over year. The company also cut 2026 adjusted EPS guidance to $1.55 to $1.75, roughly 43% lower at the midpoint, and reduced its dividend by 93% to $0.01. Hagens Berman said the stock sold off sharply afterward, while an analyst downgrade cited a need for management to rebuild investor credibility on execution and profitability.